22344-77-0Relevant articles and documents
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model
Shen, Sida,Picci, Cristina,Ustinova, Kseniya,Benoy, Veronick,Kutil, Zsófia,Zhang, Guiping,Tavares, Maurício T.,Pavlí?ek, Ji?í,Zimprich, Chad A.,Robers, Matthew B.,Van Den Bosch, Ludo,Ba?inka, Cyril,Langley, Brett,Kozikowski, Alan P.
, p. 4810 - 4840 (2021/05/07)
Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel
Synthesis of tetrahydrobenzazepinesulfonamides and their rearrangement to diarylsulfones
Ren, Hui,Zanger, Murray,McKee, James R.
, p. 355 - 363 (2007/10/03)
A new class of diarylsulfones, in which tetrahydrobenzazepine comprises one of the aromatic moieties, has been synthesized via the acid-catalyzed rearrangement of several substituted benzazepinesulfonamides. The rearrangement is normally ortho but in at l
Synthesis of 7-phenylpyrimido[5,4-d][1]benzazepin-2-ones
Chen,Gilman
, p. 663 - 666 (2007/10/02)
The syntheses of the 7-phenylpyrimido[5,4-d][1]benzazepin-2-ones 3, 4, and 5 are described. The 7-phenyl group was introduced by phenylation of the lactam nitrogen in 10, 13 and 16 respectively. One of these compounds, 5, showed moderate activity as a CNS agent.